Dissecting the role of polarity regulators in cancer through the use of mouse models

Experimental Cell Research

Volumn 328, Issue 2, 2014, Pages 249-257

  Gödde, Nathan J ^a   Pearson, Helen B ^a,b   Smith, Lorey K ^a   Humbert, Patrick O ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Cancer; Cell polarity; Mouse models

Indexed keywords

G PROTEIN SIGNALING MODULATOR 2; GUANINE NUCLEOTIDE BINDING PROTEIN; MEMBRANE PROTEIN; MULTIPROTEIN COMPLEX; PROTEIN ASSOCIATED WITH LIN7; PROTEIN KINASE LKB1; SCAFFOLD PROTEIN; TIGHT JUNCTION PROTEIN; TIGHT JUNCTION PROTEIN INADL; TIGHT JUNCTION PROTEIN PATJ; TRANSMEMBRANE PROTEIN CRUMBS; UNCLASSIFIED DRUG;

CANCER INHIBITION; CANCER THERAPY; CARCINOGENESIS; CELL FUNCTION; CELL POLARITY; CLINICAL PRACTICE; CYTOARCHITECTURE; EXPERIMENTAL MOUSE; EXPERIMENTAL NEOPLASM; GENETICALLY ENGINEERED MOUSE STRAIN; HUMAN; IN VIVO STUDY; INTERVENTION STUDY; MOUSE; MOUSE MODEL; NONHUMAN; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TISSUE STRUCTURE; ANIMAL; DISEASE COURSE; DISEASE MODEL; NEOPLASM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; CELL POLARITY; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; MICE; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84908200587     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2014.08.036     Document Type: Review

References (100)

1. R. Halaoui and L. McCaffrey, Rewiring cell polarity signaling in cancer, Oncogene, in press. http://dx.doi.org/10.1038/onc.2014.59.
2. Martin-Belmonte F., Perez-Moreno M. Epithelial cell polarity, stem cells and cancer. Nat. Rev. Cancer 2012, 12(1):23-38.
3. Humbert P.O., et al. Control of tumourigenesis by the Scribble/Dlg/Lgl polarity module. Oncogene 2008, 27(55):6888-6907.
4. Elsum I., et al. The Scribble-Dlg-Lgl polarity module in development and cancer: from flies to man. Essays Biochem. 2012, 53:141-168.
5. Godde N.J., et al. Cell polarity in motion: redefining mammary tissue organization through EMT and cell polarity transitions. J. Mammary Gland Biol. Neoplasia 2010, 15(2):149-168.
6. Bazzoun D., Lelievre S., Talhouk R. Polarity proteins as regulators of cell junction complexes: implications for breast cancer. Pharmacol. Ther. 2013, 138(3):418-427.
7. Godde N.J., et al. Scribble Modulates the MAPK/Fra1 Pathway to Disrupt Luminal and Ductal Integrity and Suppress Tumour Formation in the Mammary Gland. PLoS Genet. 2014, 10(5):e1004323.
8. Runkle E.A., Mu D. Tight junction proteins: from barrier to tumorigenesis. Cancer Lett. 2013, 337(1):41-48.
9. Hawkins E.D., Russell S.M. Upsides and downsides to polarity and asymmetric cell division in leukemia. Oncogene 2008, 27(55):7003-7017.
10. Ozdamar B., et al. Regulation of the polarity protein Par6 by TGFbeta receptors controls epithelial cell plasticity. Science 2005, 307(5715):1603-1609.
11. Xue B., et al. Loss of Par3 promotes breast cancer metastasis by compromising cell-cell cohesion. Nat. Cell Biol. 2013, 15(2):189-200.
12. Hidalgo-Carcedo C., et al. Collective cell migration requires suppression of actomyosin at cell-cell contacts mediated by DDR1 and the cell polarity regulators Par3 and Par6. Nat. Cell Biol. 2011, 13(1):49-58.
13. Kim J.Y., et al. c-Myc phosphorylation by PKCzeta represses prostate tumorigenesis. Proc. Natl. Acad. Sci. USA 2013, 110(16):6418-6423.
14. Wang Y., Hill K.S., Fields A.P. PKCiota maintains a tumor-initiating cell phenotype that is required for ovarian tumorigenesis. Mol. Cancer Res. 2013, 11(12):1624-1635.
15. McCaffrey L.M., Macara I.G. The Par3/aPKC interaction is essential for end bud remodeling and progenitor differentiation during mammary gland morphogenesis. Genes Dev. 2009, 23(12):1450-1460.
16. McCaffrey L.M., et al. Loss of the Par3 polarity protein promotes breast tumorigenesis and metastasis. Cancer Cell 2012, 22(5):601-614.
17. Williams S.E., et al. Par3-mInsc and Galphai3 cooperate to promote oriented epidermal cell divisions through LGN. Nat. Cell Biol. 2014, 16(8):758-769.
18. Facciuto F., et al. Differential expression of PDZ domain-containing proteins in human diseases-challenging topics and novel issues. FEBS J. 2012, 279(19):3538-3548.
19. Iden S., et al. Tumor type-dependent function of the par3 polarity protein in skin tumorigenesis. Cancer Cell 2012, 22(3):389-403.
20. Nolan M.E., et al. The polarity protein Par6 induces cell proliferation and is overexpressed in breast cancer. Cancer Res. 2008, 68(20):8201-8209.
21. Murray N.R., Kalari K.R., Fields A.P. Protein kinase Ciota expression and oncogenic signaling mechanisms in cancer. J. Cell. Physiol. 2011, 226(4):879-887.
22. Kusne Y., et al. Targeting aPKC disables oncogenic signaling by both the EGFR and the proinflammatory cytokine TNFalpha in glioblastoma. Sci. Signal. 2014, 7(338):ra75.
23. Paul A., et al. PKClambda/iota signaling promotes triple-negative breast cancer growth and metastasis. Cell Death Differ. 2014, 21(9):1469-1481.
24. Regala R.P., et al. Atypical protein kinase Ciota plays a critical role in human lung cancer cell growth and tumorigenicity. J. Biol. Chem. 2005, 280(35):31109-31115.
25. Regala R.P., et al. Atypical protein kinase C{iota} is required for bronchioalveolar stem cell expansion and lung tumorigenesis. Cancer Res. 2009, 69(19):7603-7611.
26. Galvez A.S., et al. Protein kinase Czeta represses the interleukin-6 promoter and impairs tumorigenesis in vivo. Mol. Cell. Biol. 2009, 29(1):104-115.
27. Feigin M.E., et al. Mislocalization of the cell polarity protein Scribble promotes mammary tumorigenesis and is associated with basal breast cancer. Cancer 2014, 74(11):3180-3194.
28. Skibinski A., et al. The hippo transducer TAZ interacts with the SWI/SNF complex to regulate breast epithelial lineage commitment. Cell Rep. 2014, 6(6):1059-1072.
29. Nakajima Y., et al. Epithelial junctions maintain tissue architecture by directing planar spindle orientation. Nature 2013, 500(7462):359-362.
30. Russ A., et al. Hugl1 and Hugl2 in mammary epithelial cells: polarity, proliferation, and differentiation. PLoS One 2012, 7(10):e47734.
31. Elsum I.A., et al. Scrib heterozygosity predisposes to lung cancer and cooperates with KRas hyperactivation to accelerate lung cancer progression in vivo. Oncogene 2013, 10.1038/onc.2013.498, in press.
32. Pearson H.B., et al. SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia. J. Clin. Invest. 2011, 121(11):4257-4267.
33. Zhan L., et al. Deregulation of scribble promotes mammary tumorigenesis and reveals a role for cell polarity in carcinoma. Cell 2008, 135(5):865-878.
34. Huebner R.J., Lechler T., Ewald A.J. Developmental stratification of the mammary epithelium occurs through symmetry-breaking vertical divisions of apically positioned luminal cells. Development 2014, 141(5):1085-1094.
35. Chiappetta G., et al. FRA-1 protein overexpression is a feature of hyperplastic and neoplastic breast disorders. BMC Cancer 2007, 7:17.
36. Tang N., et al. Control of mitotic spindle angle by the RAS-regulated ERK1/2 pathway determines lung tube shape. Science 2011, 333(6040):342-345.
37. Zigman M., et al. Zebrafish neural tube morphogenesis requires Scribble-dependent oriented cell divisions. Curr. Biol. 2011, 21(1):79-86.
38. Massimi P., et al. Differential regulation of cell-cell contact, invasion and anoikis by hScrib and hDlg in keratinocytes. PLoS One 2012, 7(7):e40279.
39. Li X., et al. Scribble-mediated membrane targeting of PHLPP1 is required for its negative regulation of Akt. EMBO Rep. 2011, 12(8):818-824.
40. Chatterjee S., et al. Dysregulation of cell polarity proteins synergize with oncogenes or the microenvironment to induce invasive behavior in epithelial cells. PLoS One 2012, 7(4):e34343.
41. Sandoval G.J., et al. Novel mechanism of tumor suppression by polarity gene discs large 1 (DLG1) revealed in a murine model of pediatric B-ALL. Cancer Immunol. Res. 2013, 1(6):426-437.
42. Yamben I.F., et al. Scrib is required for epithelial cell identity and prevents epithelial to mesenchymal transition in the mouse. Dev. Biol. 2013, 384(1):41-52.
43. Reischauer S., et al. Lgl2 executes its function as a tumor suppressor by regulating ErbB signaling in the zebrafish epidermis. PLoS Genet. 2009, 5(11):e1000720.
44. Dow L.E., et al. Loss of human Scribble cooperates with H-Ras to promote cell invasion through deregulation of MAPK signalling. Oncogene 2008, 27(46):5988-6001.
45. Brumby A.M., Richardson H.E. Scribble mutants cooperate with oncogenic Ras or Notch to cause neoplastic overgrowth in Drosophila. EMBO J. 2003, 22(21):5769-5779.
46. Zeng X., et al. Tumor suppressors Sav/Scrib and oncogene Ras regulate stem-cell transformation in adult Drosophila malpighian tubules. J. Cell. Physiol. 2010, 224(3):766-774.
47. Cordenonsi M., et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 2011, 147(4):759-772.
48. Whiteman E.L., et al. Crumbs3 is essential for proper epithelial development and viability. Mol. Cell. Biol. 2014, 34(1):43-56.
49. Cho S.H., et al. Genetic ablation of Pals1 in retinal progenitor cells models the retinal pathology of Leber congenital amaurosis. Hum. Mol. Genet. 2012, 21(12):2663-2676.
50. Jenne D.E., et al. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat. Genet. 1998, 18(1):38-43.
51. Resta N., et al. Two novel mutations and a new STK11/LKB1 gene isoform in Peutz-Jeghers patients. Hum. Mutat. 2002, 20(1):78-79.
52. Baas A.F., et al. Complete polarization of single intestinal epithelial cells upon activation of LKB1 by STRAD. Cell 2004, 116(3):457-466.
53. Spicer J., et al. Regulation of the Wnt signalling component PAR1A by the Peutz-Jeghers syndrome kinase LKB1. Oncogene 2003, 22(30):4752-4756.
54. Zhang L., et al. AMP-activated protein kinase regulates the assembly of epithelial tight junctions. PNAS 2006, 103(46):17272-17277.
55. Alessi D., Sakamoto K., Bayascas J. LKB1-dependent signaling pathways. Annu. Rev. Biochem. 2006, 75:137-163.
56. Wodarz A., Näthke I. Cell polarity in development and cancer. Nat. Cell Biol. 2007, 9:1016-1024.
57. ten Klooster J.P., et al. Mst4 and Ezrin induce brush borders downstream of the Lkb1/Strad/Mo25 polarization complex. Dev. Cell 2009, 16(4):551-562.
58. Alessi D.R., Sakamoto K., Bayascas J.R. LKB1-dependent signaling pathways. Annu. Rev. Biochem. 2006, 75:137-163.
59. Su G., et al. Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am. J. Pathol. 1999, 154(6):1835-1840.
60. Guldberg P., et al. Somatic mutation of the Peutz-Jeghers syndrome gene, LKB1/STK11, in malignant melanoma. Oncogene 1999, 18(9):1777-1780.
61. Ji H., et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 2007, 448(7155):807-810.
62. Andrade-Vieira R., et al. Loss of LKB1 expression reduces the latency of ErbB2-mediated mammary gland tumorigenesis, promoting changes in metabolic pathways. PLoS One 2013, 8(2):e56567.
63. Bardeesy N., et al. Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature 2002, 419(6903):162-167.
64. Partanen J.I., et al. Tumor suppressor function of Liver kinase B1 (Lkb1) is linked to regulation of epithelial integrity. Proc. Natl. Acad. Sci. USA 2012, 109(7):E388-E397.
65. Pearson H.B., et al. Lkb1 deficiency causes prostate neoplasia in the mouse. Cancer Res. 2008, 68(7):2223-2232.
66. Lo B., et al. Lkb1 regulates organogenesis and early oncogenesis along AMPK-dependent and -independent pathways. J. Cell Biol. 2012, 199(7):1117-1130.
67. Mukhopadhyay A., et al. Sox2 cooperates with Lkb1 loss in a mouse model of squamous cell lung cancer. Cell Rep. 2014, 8(1):40-49.
68. Tanwar P.S., et al. Loss of LKB1 and PTEN tumor suppressor genes in the ovarian surface epithelium induces papillary serous ovarian cancer. Carcinogenesis. 2013, 35(3):546-553.
69. Gao Y., et al. LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling. Proc. Natl. Acad. Sci. USA 2010, 107(44):18892-18897.
70. Bayly R., Axelrod J.D. Pointing in the right direction: new developments in the field of planar cell polarity. Nat. Rev. Genet. 2011, 12(6):385-391.
71. Wang Y. Wnt/Planar cell polarity signaling: a new paradigm for cancer therapy. Mol. Cancer Ther. 2009, 8(8):2103-2109.
72. Katoh M. WNT/PCP signaling pathway and human cancer (review). Oncol. Rep. 2005, 14(6):1583-1588.
73. Royer C., Lu X. Epithelial cell polarity: a major gatekeeper against cancer?. Cell Death Differ. 2011, 18(9):1470-1477.
74. Saburi S., et al. Functional interactions between Fat family cadherins in tissue morphogenesis and planar polarity. Development 2012, 139(10):1806-1820.
75. Mao Y., et al. Characterization of a Dchs1 mutant mouse reveals requirements for Dchs1-Fat4 signaling during mammalian development. Development 2011, 138(5):947-957.
76. Katoh M. Function and cancer genomics of FAT family genes (review). Int. J. Oncol. 2012, 41(6):1913-1918.
77. Iozzo R.V., Eichstetter I., Danielson K.G. Aberrant expression of the growth factor Wnt-5A in human malignancy. Cancer Res. 1995, 55(16):3495-3499.
78. Chan D.W., et al. Prickle-1 negatively regulates Wnt/beta-catenin pathway by promoting Dishevelled ubiquitination/degradation in liver cancer. Gastroenterology 2006, 131(4):1218-1227.
79. Lee J.H., et al. KAI1 COOH-terminal interacting tetraspanin (KITENIN), a member of the tetraspanin family, interacts with KAI1, a tumor metastasis suppressor, and enhances metastasis of cancer. Cancer Res. 2004, 64(12):4235-4243.
80. Lee J.H., et al. Suppression of progression and metastasis of established colon tumors in mice by intravenous delivery of short interfering RNA targeting KITENIN, a metastasis-enhancing protein. Cancer Res. 2005, 65(19):8993-9003.
81. Marty C., Browning D.D., Ye R.D. Identification of tetratricopeptide repeat 1 as an adaptor protein that interacts with heterotrimeric G proteins and the small GTPase Ras. Mol. Cell Biol. 2003, 23(11):3847-3858.
82. Blumer J.B., et al. Interaction of activator of G-protein signaling 3 (AGS3) with LKB1, a serine/threonine kinase involved in cell polarity and cell cycle progression: phosphorylation of the G-protein regulatory (GPR) motif as a regulatory mechanism for the interaction of GPR motifs with Gi alpha. J. Biol. Chem. 2003, 278(26):23217-23220.
83. Caussinus E., Gonzalez C. Induction of tumor growth by altered stem-cell asymmetric division in Drosophila melanogaster. Nat. Genet. 2005, 37(10):1125-1129.
84. Konno D., et al. Neuroepithelial progenitors undergo LGN-dependent planar divisions to maintain self-renewability during mammalian neurogenesis. Nat. Cell Biol. 2008, 10(1):93-101.
85. Williams S.E., et al. Asymmetric cell divisions promote Notch-dependent epidermal differentiation. Nature 2011, 470(7334):353-358.
86. Aranda V., et al. Par6-aPKC uncouples ErbB2 induced disruption of polarized epithelial organization from proliferation control. Nat. Cell Biol. 2006, 8(11):1235-1245.
87. Osanai M., et al. Epigenetic silencing of occludin promotes tumorigenic and metastatic properties of cancer cells via modulations of unique sets of apoptosis-associated genes. Cancer Res. 2006, 66(18):9125-9133.
88. Osanai M., et al. Epigenetic silencing of claudin-6 promotes anchorage-independent growth of breast carcinoma cells. Cancer Sci. 2007, 98(10):1557-1562.
89. Suzuki M., et al. Therapeutic antitumor efficacy of monoclonal antibody against Claudin-4 for pancreatic and ovarian cancers. Cancer Sci. 2009, 100(9):1623-1630.
90. Huang Y.H., et al. Claudin-3 gene silencing with siRNA suppresses ovarian tumor growth and metastasis. Proc. Natl. Acad. Sci. USA 2009, 106(9):3426-3430.
91. Doucet M.V., et al. Small-molecule inhibitors at the PSD-95/nNOS interface have antidepressant-like properties in mice. Neuropsychopharmacology 2013, 38(8):1575-1584.
92. Metodieva G., et al. CD74-dependent deregulation of the tumor suppressor scribble in human epithelial and breast cancer cells. Neoplasia 2013, 15(6):660-668.
93. Borghese F., Clanchy F.I. CD74: an emerging opportunity as a therapeutic target in cancer and autoimmune disease. Expert Opin. Ther. Targets 2011, 15(3):237-251.
94. Takagawa R., et al. High expression of atypical protein kinase C lambda/iota in gastric cancer as a prognostic factor for recurrence. Ann. Surg. Oncol. 2010, 17(1):81-88.
95. Kjaer S., et al. Adenosine-binding motif mimicry and cellular effects of a thieno[2,3-d]pyrimidine-based chemical inhibitor of atypical protein kinase C isoenzymes. Biochem. J. 2013, 451(2):329-342.
96. Rebagay G., et al. ROR1 and ROR2 in human malignancies: potentials for targeted therapy. Front. Oncol. 2012, 2:34.
97. Zhang Y., et al. Inhibition of Wnt signaling by Dishevelled PDZ peptides. Nat. Chem. Biol. 2009, 5(4):217-219.
98. Zhao R.X., Xu Z.X. Targeting the LKB1 tumor suppressor. Curr. Drug Targets 2014, 15(1):32-52.
99. Willecke M., Toggweiler J., Basler K. Loss of PI3K blocks cell-cycle progression in a Drosophila tumor model. Oncogene 2011, 30(39):4067-4074.
100. Murray N.R., Fields A.P. Atypical protein kinase C iota protects human leukemia cells against drug-induced apoptosis. J. Biol. Chem. 1997, 272(44):27521-27524.